Esketamine safe, effective for treatment-resistant depression

January 4, 2018

(HealthDay)—Esketamine seems to be efficacious and safe for patients with treatment-resistant depression (TRD), according to a study published online Dec. 27 in JAMA Psychiatry.

Ella J. Daley, M.D., from Janssen Research & Development LLC in Titusville, N.J., and colleagues conducted a phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study to examine the efficacy, safety, and dose-response of intranasal esketamine hydrochloride. A total of 67 adults with a diagnosis of and history of inadequate response to two or more antidepressants (TRD) were randomized and 60 completed two one-week double-blind treatment periods. In period 1, participants were randomized to placebo or esketamine 28, 56, or 84 mg twice weekly (33, 11, 11, and 12 participants, respectively). In period 2, 28 placebo-treated participants were re-randomized to one of the four treatment arms.

The researchers found that the change in Montgomery-Åsberg Depression Rating Scale total score was superior in all three esketamine groups versus placebo (least squares mean difference versus placebo: esketamine 28 mg: −4.2; 56 mg: −6.3; 84 mg: −9.0), with a significant ascending dose-response relationship. Despite reduced dosing frequency in the open-label phase, the improvement in depressive symptoms appeared to be sustained (−7.2).

"In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose-related," the authors write. "Results support further investigation in larger trials."

Several authors disclosed financial ties to Janssen Research & Development LLC, which funded the study.

Explore further: Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

More information: Abstract/Full Text
Editorial (subscription or payment may be required)

Related Stories

Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

December 28, 2016
(HealthDay)—For patients with Parkinson's disease (PD) receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, ...

Varenicline linked to reduction in heavy drinking in men

December 21, 2017
(HealthDay)—Varenicline is associated with reduced heavy drinking among men and with increased smoking abstinence, according to a study published online Dec. 20 in JAMA Psychiatry.

Intranasal omalizumab does not increase serum IgE levels

November 22, 2017
(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published ...

Secukinumab effective for moderate / severe scalp psoriasis

September 29, 2017
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...

Naloxegol has no effect on opioid dose in opioid-tied constipation

September 21, 2017
(HealthDay)—For patients with noncancer pain and opioid-induced constipation (OIC), naloxegol has no clinically relevant effect on patient-reported pain levels or mean daily opioid dose, according to research published ...

Lisdexamfetamine dimesylate has early benefit in binge eating

August 4, 2017
(HealthDay)—Lisdexamfetamine dimesylate (LDX) is associated with early improvement in efficacy measures in adults with binge-eating disorder (BED), according to research published in the August issue of the International ...

Recommended for you

Regular problem solving does not protect against mental decline

December 10, 2018
The well known 'use it or lose it' claim has been widely accepted by healthcare professionals, but researchers in the Christmas issue of The BMJ find that regularly doing problem solving activities throughout your lifetime ...

Early career choices appear to influence personality, study finds

December 10, 2018
In the state of Baden-Wurttemberg, Germany, 16-year-old students in middle-track schools decide whether to stay in school to pursue an academic career or enroll in a vocational training program. A new study offers evidence ...

When scientists push people to their tipping point

December 10, 2018
You probably overestimate just how far someone can push you before you reach your tipping point, new research suggests.

Internet therapy apps reduce depression symptoms, study finds

December 7, 2018
In a sweeping new study, Indiana University psychologists have found that a series of self-guided, internet-based therapy platforms effectively reduce depression.

Gender bias sways how we perceive competence in faces

December 7, 2018
Faces that are seen as competent are also perceived as more masculine, according to research published in Psychological Science, a journal of the Association for Psychological Science.

Targeted cognitive training benefits patients with severe schizophrenia

December 7, 2018
Schizophrenia is among the most difficult mental illnesses to treat, in part because it is characterized by a wide range of dysfunction, from hallucinations and mood disorders to cognitive impairment, especially verbal and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.